The Cedars-Sinai Cancer Blood & Marrow Transplant Program’s one-year patient survival rate exceeded expectations compared to transplant centers in the U.S. whose similar patients underwent allogeneic transplants, according to a national report that tracks those outcomes.
A critical shortage of blood, which has stretched supplies thin nationwide, threatens hospitals' ability to provide many types of patient care. The Red Cross has just declared the first-ever national blood crisis. A blood bank director with nearly 40 years of experience urges every eligible person to step up and make an appointment to donate as soon as possible.
A defective gene, normally found in blood cancers, could be treated with drugs already available for cancers with similar gene defects, scientists at Queen’s University Belfast and the University of Birmingham have revealed.
New research in the January 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined the impact of septic shock on people with hematologic malignancies, finding 67.8% died in fewer than 28 days and only 19.4% remained alive after 90 days.
Over the course of more than three decades studying sickle cell disease and caring for patients, Thomas Coates, MD, has learned an important lesson: listen to the mothers. It is their detailed accounts of their children’s pain that inspired his current research focus.
The January 2022 issue of Toxicological Sciences launches the New Year with investigations in clinical and translational toxicology, as well as emerging technologies, methods, and models.
Aberrant splicing of messenger RNAs encoding surface antigen CD22 leads to downregulation of this protein in pediatric B-lymphoblastic leukemia (B-ALL), rendering malignant cells resistant to the effects of CD22-directed immunotherapies, according to a recent study by researchers at Children’s Hospital of Philadelphia (CHOP). The findings could allow oncologists to screen new patients to see if their leukemic cells contain alternatively spliced CD22 mRNA variants, which could reveal which patients might not respond to anti-CD22 therapies and would need alternative treatment plans. The study was published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.
Computer simulations from UC San Diego School of Medicine reveal the action mechanism and substrate specificity of an important blood enzyme. These findings open the door for new therapeutics against cardiovascular disease, and further support a unifying theory of phospholipase function.
South African geneticist Ambroise Wonkam, M.D., Ph.D., D.Med.Sc., has been selected as Johns Hopkins Medicine’s director of the Department of Genetic Medicine and the McKusick-Nathans Institute of Genetic Medicine.
A molecular building block of many animal proteins, the amino acid valine, plays a key role in cancerous growth seen in T cell acute lymphoblastic leukemia, a new study shows.
Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Icahn School of Medicine at Mount Sinai showed for the first time that artificial intelligence (AI) algorithms can detect signs of these clots in electrocardiograms (EKGs), a finding which may one day help doctors with screening.
Although unproven, this novel sickle cell therapy serves as a potential cure. More measures need to be taken to determine long-term function and organ improvement.
UC Davis Health researchers showed that blocking IL-6 and TNF cytokines provides a more effective approach to preventing life-threatening graft-versus-host-disease, an inflammatory condition that develops in patients after their allogeneic hematopoietic stem cell transplantation.
A new review explores the physiology behind and proposed management strategies for body-wide symptoms of the post-acute sequelae of SARS-CoV-2 (PASC), otherwise known as “long COVID.” The review is published ahead of print in the American Journal of Physiology-Cell Physiology.
Researchers at Washington University School of Medicine in St. Louis have shown, in a small clinical trial, that an immunotherapy harnessing pre-activated natural killer cells can help some children and young adults with recurrent AML and few other treatment options.
A drug combination can safely prevent transplanted stem cells (graft) from attacking the recipient’s (host) body, allowing them to develop into healthy new blood and immune cells, a new study shows.
Blood clots or thromboembolic complications in patients with COVID-19 are associated with increased levels of various proteins that cause blood to clot, compared with people with blood clots unrelated to COVID-19, according to a small study by Yale Cancer Center researchers. These findings may offer insights into novel therapeutic strategies to treat patients with COVID-19 related blood clots. The findings were reported today at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia.